Shifting China Sands Posing Challenge to Novo Nordisk
This article was originally published in PharmAsia News
Executive Summary
While foreign exchange effects are flattering Novo Nordisk's China sales, the Danish firm sees challenges in this key emerging market over the mid-term from a mix of shifting market conditions, although a recovery is expected given strong underlying fundamentals.